Inovio Pharmaceuticals (INO) Total Liabilities (2010 - 2026)

Inovio Pharmaceuticals has disclosed Total Liabilities across 17 years of filings, most recently posting $45.0 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 13.37% year-over-year to $45.0 million; the TTM figure through Jun 2026 stood at $45.0 million (up 13.37% YoY), while the FY2025 annual figure was $50.2 million, up 12.35% from the prior year.
• Total Liabilities came in at $45.0 million for Q2 2026 at Inovio Pharmaceuticals, up from $43.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $161.7 million in Q2 2022 to a low of $33.5 million in Q3 2024.
• Average Total Liabilities over 5 years is $65.8 million, with a median of $51.9 million recorded in 2023.
• Year-over-year, Total Liabilities plunged 60.63% in 2023 and jumped 130.03% in 2025.
• Over 5 years, Total Liabilities stood at $126.2 million in 2022, then tumbled by 57.52% to $53.6 million in 2023, then declined by 16.62% to $44.7 million in 2024, then rose by 12.35% to $50.2 million in 2025, then declined by 10.35% to $45.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $45.0 million in Q2 2026, $43.7 million in Q1 2026, and $50.2 million in Q4 2025.